Biopharma Co. Escapes Investor Suit Over Drug Approval Lies

By Sydney Price

Biopharmaceutical company Spero Therapeutics Inc. has escaped a proposed investor class action accusing it of concealing warning signs that it would not secure regulatory approval of one of its drugs, with the court ruling that Spero's interactions with the U.S. Food and Drug Administration do not indicate Spero should have known its application would be rejected.

 Order attached | Read full article » | Save to favorites »